Researchers at the University of Sydney have reported experimental nose drops that improved learning and memory in aged mice and prevented memory loss in a mouse model of Alzheimer's disease. The work, from the laboratory of Professor Greg Neely at the Charles Perkins Centre, was published in Advanced Science.
The drops deliver messenger RNA packaged in lipid nanoparticles, the same general platform used in COVID-19 vaccines. The mRNA carries instructions for brain-derived neurotrophic factor (BDNF), a naturally occurring protein that supports neuron survival, plasticity and memory formation. Levels of BDNF are reduced with ageing and in Alzheimer's disease. The researchers describe the nose as acting like a drug factory, producing the protein that can then reach the brain.
In aged mice, treated animals performed similarly to young mice on standardised tests of working memory, spatial memory and object recognition. In the 5XFAD model, which carries genetic mutations and shows Alzheimer's-like brain changes from about two months of age, mice that received the drops twice weekly from two months showed no further cognitive decline by four months. The team also reported increased formation of new neurons in the hippocampus, a region central to learning and memory, and said no major side effects were seen.
A notable point is that the treatment appeared to preserve brain function without reducing amyloid plaques. Professor Neely argued that this could allow the approach to complement anti-amyloid therapies rather than replace them, since some people have plaques without dementia and tend to have higher BDNF levels. Nasal delivery is also attractive because it may reach the brain without surgery or injections, sidestepping the blood-brain barrier that blocks many drugs.
The researchers are clear that this remains preclinical. Professor Neely said human noses differ from mouse noses and that safety studies in animals must come first. The team says it hopes to move to human trials within two years.